Placebo Response in Trials of Drug Treatments for Cancer-related Fatigue: a Systematic Review, Meta-analysis and Meta-regression

Overview

Journal BMJ Support Palliat Care

Publisher BMJ Publishing Group

Specialties Critical Care
Pharmacology
Psychiatry

Date 2020 Feb 13

PMID 32046962

Citations 10

Authors

Rocio Roji

Patrick Stone

Federico Ricciardi

Bridget Candy

Affiliations

Soon will be listed here.

Abstract

Background: Cancer-related fatigue (CRF) is one of the most distressing symptoms experienced by patients. There is no gold standard treatment, although multiple drugs have been tested with little evidence of efficacy. Randomised controlled trials (RCTs) of these drugs have commented on the existence or size of the placebo response (PR). The objective of this systematic review was to establish the magnitude of the PR in RCTs of drugs to relieve CRF and to identify contributing factors.

Method: RCTs were included in which the objective was to treat CRF. A meta-analysis was conducted using the standardised mean change (SMC) between baseline and final measurement in the placebo group. To explore factors that may be associated with the PR (eg, population or drug), a meta-regression was undertaken. Risk of bias was assessed using the revised Cochrane tool.

Results: From 3916 citations, 30 relevant RCTs were identified. All had limitations that increased their risk of bias. The pooled SMC in reduction in fatigue status in placebo groups was -0.23 (95% confidence intervals -0.42 to -0.04). None of the variables analysed in the meta-regression were statistically significant related to PR.

Conclusion: There is some evidence, based on trials with small samples, that the PR in trials testing drugs for CRF is non-trivial in size and statistically significant. We recommend that researchers planning drug studies in CRF should consider implementing alternative trial designs to better account for PR and decrease impact on the study results.

Citing Articles

Working with patients' treatment expectations - what we can learn from homeopathy.

Wilhelm M, Hermann C, Rief W, Schedlowski M, Bingel U, Winkler A Front Psychol. 2024; 15:1398865.

PMID: 38860049 PMC: 11163137. DOI: 10.3389/fpsyg.2024.1398865.

Putting Methylphenidate for Cancer-Related Fatigue to Rest?.

Chin-Yee N, Yennurajalingam S, Zimmermann C J Clin Oncol. 2024; 42(20):2363-2366.

PMID: 38771985 PMC: 11520668. DOI: 10.1200/JCO.24.00707.

Methylphenidate Versus Placebo for Treating Fatigue in Patients With Advanced Cancer: Randomized, Double-Blind, Multicenter, Placebo-Controlled Trial.

Stone P, Minton O, Richardson A, Buckle P, Enayat Z, Marston L J Clin Oncol. 2024; 42(20):2382-2392.

PMID: 38757263 PMC: 11227299. DOI: 10.1200/JCO.23.02639.

Predictors of placebo response in three large clinical trials of the V1a receptor antagonist balovaptan in autism spectrum disorder.

Tobe R, Zhu Y, Gleissl T, Rossomanno S, Veenstra-VanderWeele J, Smith J Neuropsychopharmacology. 2023; 48(8):1201-1216.

PMID: 37045991 PMC: 10267133. DOI: 10.1038/s41386-023-01573-9.

Management of Fatigue in Patients with Advanced Cancer.

Stone P, Candelmi D, Kandola K, Montero L, Smetham D, Suleman S Curr Treat Options Oncol. 2023; 24(2):93-107.

PMID: 36656503 PMC: 9883329. DOI: 10.1007/s11864-022-01045-0.

References

Roth A, Nelson C, Rosenfeld B, Scher H, Slovin S, Morris M . Methylphenidate for fatigue in ambulatory men with prostate cancer. Cancer. 2010; 116(21):5102-10. PMC: 3632439. DOI: 10.1002/cncr.25424. View

Bower J . Cancer-related fatigue--mechanisms, risk factors, and treatments. Nat Rev Clin Oncol. 2014; 11(10):597-609. PMC: 4664449. DOI: 10.1038/nrclinonc.2014.127. View

Richard P, Fleshner N, Bhatt J, Hersey K, Chahin R, Alibhai S . Phase II, randomised, double-blind, placebo-controlled trial of methylphenidate for reduction of fatigue levels in patients with prostate cancer receiving LHRH-agonist therapy. BJU Int. 2014; 116(5):744-52. DOI: 10.1111/bju.12755. View

Bruera E, Valero V, Driver L, Shen L, Willey J, Zhang T . Patient-controlled methylphenidate for cancer fatigue: a double-blind, randomized, placebo-controlled trial. J Clin Oncol. 2006; 24(13):2073-8. DOI: 10.1200/JCO.2005.02.8506. View

Lucas V, Booth S . The importance of placebo effects in enhancing palliative care interventions. BMJ Support Palliat Care. 2014; 4(2):212-216. DOI: 10.1136/bmjspcare-2013-000571. View

Lee E, Muzikansky A, Drappatz J, Kesari S, Wong E, Fadul C . A randomized, placebo-controlled pilot trial of armodafinil for fatigue in patients with gliomas undergoing radiotherapy. Neuro Oncol. 2016; 18(6):849-54. PMC: 4864265. DOI: 10.1093/neuonc/now007. View

Barton D, Liu H, Dakhil S, Linquist B, Sloan J, Nichols C . Wisconsin Ginseng (Panax quinquefolius) to improve cancer-related fatigue: a randomized, double-blind trial, N07C2. J Natl Cancer Inst. 2013; 105(16):1230-8. PMC: 3888141. DOI: 10.1093/jnci/djt181. View

Zhang Z, Xu X, Ni H . Small studies may overestimate the effect sizes in critical care meta-analyses: a meta-epidemiological study. Crit Care. 2013; 17(1):R2. PMC: 4056100. DOI: 10.1186/cc11919. View

Agid O, Siu C, Potkin S, Kapur S, Watsky E, Vanderburg D . Meta-regression analysis of placebo response in antipsychotic trials, 1970-2010. Am J Psychiatry. 2013; 170(11):1335-44. DOI: 10.1176/appi.ajp.2013.12030315. View

10.

Cruciani R, Zhang J, Manola J, Cella D, Ansari B, Fisch M . L-carnitine supplementation for the management of fatigue in patients with cancer: an eastern cooperative oncology group phase III, randomized, double-blind, placebo-controlled trial. J Clin Oncol. 2012; 30(31):3864-9. PMC: 3478577. DOI: 10.1200/JCO.2011.40.2180. View

11.

Lee S, Walker J, Jakul L, Sexton K . Does elimination of placebo responders in a placebo run-in increase the treatment effect in randomized clinical trials? A meta-analytic evaluation. Depress Anxiety. 2004; 19(1):10-9. DOI: 10.1002/da.10134. View

12.

Mucke M, Mochamat , Cuhls H, Peuckmann-Post V, Minton O, Stone P . Pharmacological treatments for fatigue associated with palliative care: executive summary of a Cochrane Collaboration systematic review. J Cachexia Sarcopenia Muscle. 2016; 7(1):23-7. PMC: 4799864. DOI: 10.1002/jcsm.12101. View

13.

Kirsch I . Are drug and placebo effects in depression additive?. Biol Psychiatry. 2000; 47(8):733-5. DOI: 10.1016/s0006-3223(00)00832-5. View

14.

Ashrafi F, Mousavi S, Karimi M . Potential Role of Bupropion Sustained Release for Cancer-Related Fatigue: a Double-Blind, Placebo-Controlled Study. Asian Pac J Cancer Prev. 2018; 19(6):1547-1551. PMC: 6103561. DOI: 10.22034/APJCP.2018.19.6.1547. View

15.

Kessels R, Mozer R, Bloemers J . Methods for assessing and controlling placebo effects. Stat Methods Med Res. 2017; 28(4):1141-1156. DOI: 10.1177/0962280217748339. View

16.

Auret K, Schug S, Bremner A, Bulsara M . A randomized, double-blind, placebo-controlled trial assessing the impact of dexamphetamine on fatigue in patients with advanced cancer. J Pain Symptom Manage. 2008; 37(4):613-21. DOI: 10.1016/j.jpainsymman.2008.03.016. View

17.

Cruciani R, Dvorkin E, Homel P, Culliney B, Malamud S, Lapin J . L-carnitine supplementation in patients with advanced cancer and carnitine deficiency: a double-blind, placebo-controlled study. J Pain Symptom Manage. 2008; 37(4):622-31. DOI: 10.1016/j.jpainsymman.2008.03.021. View

18.

Spathis A, Fife K, Blackhall F, Dutton S, Bahadori R, Wharton R . Modafinil for the treatment of fatigue in lung cancer: results of a placebo-controlled, double-blind, randomized trial. J Clin Oncol. 2014; 32(18):1882-8. DOI: 10.1200/JCO.2013.54.4346. View

19.

Furukawa T, Cipriani A, Atkinson L, Leucht S, Ogawa Y, Takeshima N . Placebo response rates in antidepressant trials: a systematic review of published and unpublished double-blind randomised controlled studies. Lancet Psychiatry. 2016; 3(11):1059-1066. DOI: 10.1016/S2215-0366(16)30307-8. View

20.

Morrow G, Hickok J, Roscoe J, Raubertas R, Andrews P, Flynn P . Differential effects of paroxetine on fatigue and depression: a randomized, double-blind trial from the University of Rochester Cancer Center Community Clinical Oncology Program. J Clin Oncol. 2003; 21(24):4635-41. DOI: 10.1200/JCO.2003.04.070. View